Genebox Secures Nearly RMB 100 Million Series A Funding to Advance Its Digital Health Management Platform

VCBeat has learned that Genebox, a digital health management platform, recently completed its Series A financing round of nearly RMB 100 million, led by Century Capital. Previously, the company secured an angel round of RMB 36 million, primarily invested by Dashenlin, a chain pharmacy listed on the Shanghai Stock Exchange.

Founded in May 2018, Genebox uses genetic testing as an entry point to innovate around its core products, providing consumers with customized health management services on a family basis. Since 2019, Genebox has iterated in two major directions to better meet consumer needs.

On one hand, Genebox employs high-density microarray technology to provide multi-dimensional interpretive insights, catering to the diverse needs of various populations. Within the Genebox app, hundreds of genetic testing items are categorized into multiple modules, allowing consumers to flexibly purchase tests based on their specific requirements. After completing the initial testing, users can unlock additional test results at any time according to their interests, embodying Genebox’s original vision of “one-time testing, lifelong benefits.”

On the other hand, based on genetic testing results, Genebox provides users with family-oriented, customized health management services spanning multiple vertical sectors—including insurance, medical check-ups, and vitamins—to help address practical health concerns, reflecting its product philosophy: “A Better Life Begins with Genetic Testing.”

Li Zhi, founder of Genebox, believes that personalization is a major pain point in the field of health management. Genebox positions itself as a digital health management platform, leveraging users’ genetic data to imbue its health management services with intrinsic personalization. It is reported that the customized health management services have received positive feedback and recognition from users. The company expects to achieve per-user profitability by the end of this year or early next year, having served over 1 million consumers in 2020. In Li Zhi’s view, the rapid expansion of business scale is a key reason why Genebox has attracted capital interest.

Furthermore, Genebox’s team is primarily composed of graduates from world-class universities such as Peking University, Tsinghua University, Shanghai Jiao Tong University, Wuhan University, Columbia University, and the University of Cambridge. The company’s core members possess strong foundational competencies, technical expertise, and R&D innovation capabilities. Li Zhi believes that digital health management is a nascent sector, with no mature products available for reference either domestically or internationally. At this stage, the team’s foundational competencies, interdisciplinary backgrounds, accurate understanding of user needs, and rapid responsiveness are critical factors. “The Genebox team precisely possesses these comprehensive capabilities.”

It is understood that following this round of financing, the company will further refine the product experience of Genebox, fully leverage the strategic resources of shareholders such as Dashenlin and Grand Capital, optimize its supply chain, and provide users with an enhanced health management service experience.

As internet technology continues to mature and industrialize, and as life sciences research advances with greater translation of results into practical applications, the broader health sector will see the emergence of more exciting business models. Ordinary consumers will likely gain access to higher-quality, personalized health management services at lower costs. Li Zhi emphasizes that the essence of Genebox’s products is to use genetic testing as an entry point, integrating internet technology with life sciences. By leveraging genetic data that reflects each individual’s fundamental biological traits, Genebox aims to provide customized, high-quality health management services to hundreds of millions of families, thereby meeting consumers’ growing fundamental demand for a “better life and healthier living.”

“Currently, in the broader health and wellness sector, there is no internet platform dedicated to serving consumer-end (C-end) users—a market opportunity worth hundreds of billions of dollars. By leveraging genetic testing as an entry point, Genebox is poised to rapidly fill this market gap through technological and product innovation, positioning itself as the foundational infrastructure for the next decade’s era of digital health,” said Li Zhi.